ERBB2 and breast carcinoma: The human breast cancer cell lines MDA-MB-231 and HS578T were chosen because they do not overexpress the HER-2 receptor, to avoid the consequences on cell survival secondary to the loss of Grp94-mediated delivery of HER-2 molecules at plasmalemma [15].